molecules of the month


selective oral LTA4H metalloenzyme inhibitor

in multiple inflamm. Ph. II incl. colitis + NASH

1800 cmpd fragment screen + frag. merging

J. Med. Chem., Feb. 16, 2021

Novartis, Basel, CH

1 min read

2. The Novartis LTA4H metalloenzyme inhibitor, LYS006, is a selective oral agent in multiple Ph. II studies to treat inflammatory diseases including ulcerative colitis and NASH. The starting points for this picomolar inhibitor were identified through a fragment based approach using differential scanning fluorimetry (DSF) as an initial binding assay, confirming hits with X-ray crystallography. Structure based fragment-merging led to a remarkably potent amine lead, and early hERG and CYP inhibition signals were dealt with by introducing a carboxylic acid to the molecule.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: